Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NorPACT-1: Neoadjuvant Chemotherapy in Resectable Pancreatic Head Cancer
NCT02919787Phase 3Active, not recruiting
- Sponsor
- Oslo University Hospital
- Start
- Sep 2016
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 4
01
Overview
A Phase 3 trial of fluorouracil, oxaliplatin, irinotecan in pancreatic ductal adenocarcinoma (PDAC), sponsored by Oslo University Hospital. Started Sep 2016; status: active, not recruiting.
02
Drugs
fluorouraciloxaliplatinirinotecan
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02919787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919787.